We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+30.48%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$621M
AUM Growth
+$72.3M
Cap. Flow
+$31.9M
Cap. Flow %
5.14%
Top 10 Hldgs %
33.04%
Holding
112
New
30
Increased
19
Reduced
32
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$17.5M
2
NVMI
Nova
NVMI
+$15.3M
3
GLBE icon
Global E Online
GLBE
+$9.72M
4
TBLA icon
Taboola.com
TBLA
+$6.52M
5
META icon
Meta Platforms (Facebook)
META
+$6.21M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.82M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.35M
3
AMZN icon
Amazon
AMZN
+$5.55M
4
IRON icon
Disc Medicine
IRON
+$5.23M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$4.67M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Technology 15.8%
3 Miscellaneous 13.36%
4 Communication Services 3.76%
5 Consumer Discretionary 3.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETNB
51
DELISTED
89bio
ETNB
$4.56M 0.73%
408,674
+89,373
+28% +$821K
SEDG icon
52
SolarEdge
SEDG
$2.23B
$4.49M 0.72%
+48,000
New +$4.37M
ALPN
53
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.48M 0.72%
234,841
+54,841
+30% +$762K
ARWR icon
54
Arrowhead Research
ARWR
$9.57B
$4.43M 0.71%
+144,899
New +$3.85M
ENPH icon
55
CALL
Enphase Energy
ENPH
$4.8B
$4.24M 0.68%
+32,100
New +$3.4M
VTGN icon
56
VistaGen Therapeutics
VTGN
$10.4M
$4.16M 0.67%
808,550
+708,550
+709% +$2.68M
ALNY icon
57
CALL
Alnylam Pharmaceuticals
ALNY
$32.4B
$3.83M 0.62%
+20,000
New +$3.41M
FROG icon
58
JFrog
FROG
$11.5B
$3.8M 0.61%
+109,905
New +$2.97M
PTCT icon
59
PTC Therapeutics
PTCT
$5.63B
$3.76M 0.61%
136,525
-81,934
-38% -$1.87M
UPWK icon
60
Upwork
UPWK
$1.07B
$3.76M 0.61%
+252,784
New +$3.26M
GSK icon
61
GSK
GSK
$102B
$3.71M 0.6%
100,000
– –
PLRX icon
62
Pliant Therapeutics
PLRX
$69.4M
$3.51M 0.56%
193,554
+37,420
+24% +$569K
ENLT icon
63
Enlight Renewable Energy
ENLT
$10.6B
$3.24M 0.52%
+169,280
New +$2.65M
CYTK icon
64
CALL
Cytokinetics
CYTK
$9.64B
$2.99M 0.48%
35,800
-29,200
-45% -$1.06M
AMLX icon
65
Amylyx Pharmaceuticals
AMLX
$3.72B
$2.7M 0.44%
183,650
-10,000
-5% -$153K
PFE icon
66
Pfizer
PFE
$158B
$2.59M 0.42%
90,000
– –
SRPT icon
67
CALL
Sarepta Therapeutics
SRPT
$2.17B
$2.55M 0.41%
+26,400
New +$2.53M
SEDG icon
68
CALL
SolarEdge
SEDG
$2.23B
$2.51M 0.4%
26,800
-26,700
-50% -$2.43M
PRTA icon
69
CALL
Prothena Corp
PRTA
$433M
$2.48M 0.4%
+68,200
New +$2.63M
HOWL icon
70
Werewolf Therapeutics
HOWL
$46.7M
$2.42M 0.39%
626,810
– –
PMN icon
71
ProMIS Neurosciences
PMN
$119M
$2.11M 0.34%
73,362
– –
ICL icon
72
ICL Group
ICL
$7.16B
$2.1M 0.34%
420,000
-50,000
-11% -$255K
AVGO icon
73
Broadcom
AVGO
$1.66T
$2.01M 0.32%
+18,000
New +$1.7M
KZR
74
DELISTED
Kezar Life Sciences
KZR
$1.94M 0.31%
205,168
– –
VIGL
75
DELISTED
Vigil Neuroscience
VIGL
$1.81M 0.29%
+535,120
New +$2.75M
1 2
3
4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sphera Funds Management held 112 positions worth $621M, up 13% from $549M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management deployed $31.9M of net new capital in Q4 2023, opening 30 new positions and adding to 19 existing holdings. Its largest new stake was Nova: 132,000 shares worth $18.1M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 61% a quarter earlier, followed by Technology and Miscellaneous.

On the sell side, the largest reduction was AstraZeneca, an estimated $6.82M trimmed.

  • Sphera Funds Management's largest Q4 2023 buy was Nova: 132,000 shares worth $18.1M.
  • Sphera Funds Management added most to Teva Pharmaceutical Industries Limited in Q4 2023, an estimated $17.5M increase.
  • Sphera Funds Management's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $6.82M.
  • Sphera Funds Management fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.35M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $621M portfolio in Q4 2023.
  • Sphera Funds Management opened 30 new positions and closed 13 in Q4 2023.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $621M.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.